Evergreen RSV Vaccine Study

Janssen EVERGREEN Respiratory Syncytial Virus (RSV) Vaccine Study

Disease of Interest: Respiratory Syncytial Virus (RSV)

Principal Investigator: Forest Arnold, DO

Key Personnel: Daniya Sheikh, MD; Steven Gootee, MHI

The Center of Excellence for Research in Infectious Diseases at the University of Louisville was selected as a site for the EVERGREEN RSV Vaccine Clinical Study. This is a medical research study to evaluate the effectiveness of an investigational respiratory syncytial virus (RSV) vaccine in protecting against lower respiratory tract disease caused by RSV.

RSV is a highly contagious and potentially life-threatening respiratory virus that affects more than 64 million people globally each year. RSV remains a major global public health concern and a cause of serious respiratory illness in all age groups, with the most severe complications seen in older adults and young children.

PI Study Presentation


Actively Seeking Study Participants

Help us to find a way to prevent RSV disease

Thank you for your interest in participating in the EVERGREEN Vaccine Study. CERID is currently seeking participants age 65 and older. If you fall into this age group and are interested in participating in this clinical study, please fill out the form below. This will add you to our email list where you will receive emails with study updates and enrollment information.

Once registered for the study email list you will be invited to join an online webinar with the Principal Investigator, Dr. Forest Arnold. This webinar will provide useful information to interested participants and feature a question-and-answer panel.

Sign up

Individuals actively participating in another clinical trial involving an investigational product will be excluded from participating in this study.

Study Contact

The research team for this study can be reached by email at: uoflvacc@louisville.edu or by calling 502-209-8054.